- Guggenheim updates Intellia Therapeutics (NASDAQ:NTLA) to a “Buy” recommendation despite a “hold” action, indicating a positive yet cautious investment outlook.
- Intellia reports a second-quarter loss of $0.99 per share, surpassing expectations with revenues rising to $14.2 million, showcasing financial improvement and potential.
- The company’s progress in phase III studies for NTLA-2001 and NTLA-2002, targeting ATTR and HAE programs, reflects positively on its pipeline development and stock price increase.
Intellia Therapeutics (NASDAQ:NTLA) is a biotechnology company focused on developing gene-editing therapies using CRISPR technology. The company aims to treat genetic diseases by editing genes directly within the body. Intellia’s competitors include other biotech firms like CRISPR Therapeutics and Editas Medicine, which are also exploring CRISPR-based treatments.
On August 13, 2025, Guggenheim updated its rating for NTLA to a “Buy” recommendation, with the stock priced at $10.86. Despite this positive outlook, the action remains as “hold.” This suggests that while the stock is seen as a good investment, there may be factors causing investors to remain cautious.
Intellia’s recent financial performance shows promise. The company reported a second-quarter loss of $0.99 per share, which was better than the anticipated loss of $1.03 per share. This is an improvement from the previous year’s loss of $1.31 per share. The company’s revenues rose to $14.2 million, surpassing expectations and doubling from the previous year, mainly due to gains from collaborations.
The stock for NTLA is currently priced at $11.21, reflecting an increase of 3.22% with a change of $0.35. Today, the stock has fluctuated between a low of $10.98 and a high of $11.39. Over the past year, NTLA has reached a high of $24.16 and a low of $5.90. The company’s market capitalization stands at approximately $1.2 billion, with a trading volume of 776,813 shares on the NASDAQ exchange.
Intellia is making significant progress in its pipeline, with phase III studies for NTLA-2001 and NTLA-2002 advancing well. These studies target ATTR and HAE programs and are meeting key enrollment milestones. This progress in their pipeline could be a factor in Guggenheim’s updated rating and the stock’s recent price increase.
